Chiglitazar/Metformin in Non-obese Women With PCOS
Status:
Enrolling by invitation
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorders in
women of reproductive age, and its prevalence rate is from 9% (NIH criteria) to 18%
(Rotterdamcriteria). It is clinically characterized by hyperandrogenism, persistent
anovulation, and polycystic ovarian changes. Moreover it is often accompanied by insulin
resistance and obesity. Now, metformin is not only an antihyperglycemic drug, it also
corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome. Chiglitazar is
a novel peroxisome proliferation activated receptor (PPAR) agonist. Treatment of type 2
diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin
sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
However, there is limited evidence for its treatment of insulin resistance in women with
PCOS. Therefore, we applied chiglitazar and metformin to two groups of PCOS patients to
understand their effects on insulin resistance.